Montelukast Sodium
Brand Formulations & Prices
230 brands sorted by unit price
Montela
Pulmokast
Nozma ODT
Airway
Arokast
Arovent ODT
Asmont
Freegest
G-Montelukast
Loctril
M-Kast
Medikast
Monocast
Mont-R
Montela
Montex
Recast
Tekast ODT
Trilock OFT
Molukat
Montek
Trilock
Luminus
Lumona FT
Aeron FT
AirFlow
Airup
Arokast FT
Asmont
Croma
Lotem
M-lucas
Monalast ODT
Monas
Monasic
Monfast ODT
Monkon
Monofast
Montair ODT
Montekast
Montelon Kidz
Montene
Montezen
MontiFast
Montica
Montinex
Montiva
Montril
Odmon
Proair
Provair ODT
Telukast
Ventair
Reversair
Monas OFT
Breasy
Nozma ODT
Airup
Airway
Amikast
Arokast
Asmatab
Asthmacare
Brocast
Freegest
Liam
Loctril
Lotem
M-Kast
Medikast
Mon
Monalast
Moneka
Monkon
Monocast
Montair ODT
Montek
Monteluk
Montenaaf ODT
Montex
Montica
Montilab
Montril
Pulmont
Recast
Tekast
Xyflo
Molukat
Croma
Trilock
B Easy
Luminus
Monasic
MontiFast
Aeron FT
Arokast FT
Arovent
Lumona FT
M-lucas
Monas
Monfast ODT
Monprox OFT
Montelon
Montene
Montilab
Montinex
Montiva
Odmon
Provair ODT
Reversair
Telukast
Trilock OFT
Monas OFT
AirFlow
G-Montelukast
Maxair
Montela
Mokast
Xyflo
Breathair
Ezevent
Lumona
Montezen
Prikast
Ventair
Molukat
Liam
Airmont
Asmatab
M-K
Flomont
Ambkust
Asmont
BioMonas
Leokast
Lukas
Molicust
Molly
Proair
Tmon
Monark
Ventilast
Aircast
Amikast
Antaluk
B Easy
Breasy
Centokast
Croma
Edron
Ezair
Lotem
Lungair
Medikast
Mon-X
Monalast
Moneka
Monofast
Monovas
Monprox OFT
Mont-R
Monteluk
Montison
Nozma
Proximont
Pulmokast
Recast
SB-Monec
Salkast
Tekast
Monprox
Montilet
Pulmont
Airup
Arokast
Asthmacare
Brocast
Freegest
Loctril
M-Kast
MTS
Monasic
Montekast
Montelon
Montex
MontiFast
Montica
Montium
Montiva
Montoz
Odmon
Silmon
Telukast CT
Trilock CT
Mon
Airway
Lumenta
Luminus
Luxem
M-lucas
Maxair
Montek
Trilock
Xyflo
Aeron
AirFlow
Arovent
Monas
Monfast
Monocast
Montair
Montenaaf
Montene
Montilab
Montinex
Montinex R
Montril
Provair
Reversair
Telukast
Montinex Fast
Reversair CT
Sinlair
Monkon
Loctril
Trilock
Aeron
Lumona
Monocast
Provair
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAeron is indicated for:
Prophylaxis and chronic treatment of asthma
Acute prevention of Exercise-Induced Bronchoconstriction (EIB)
Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis
Adults and adolescents with asthma or seasonal allergic rhinitis:
The dosage for adults and adolescents 15 years of age and older
: Montelukast 10 mg tablet once daily.
Pediatric patients with asthma or seasonal allergic rhinitis:
The dosage for pediatric patients 6 to 14 years of age
: Montelukast 5 mg tablet once daily.
The dosage for pediatric patients 2 years to 5 years of age
: Montelukast 4 mg tablet once daily.
The dosage for pediatric patients 6 months to 5 years of age
: Montelukast 4 mg oral granules once daily. This can be administered either directly in the mouth, or mixed with a spoonful of cold water or soft food at room temperature
Use in the pediatric patient
: The safety and efficacy of Montelukast have been established in adequate and well-controlled studies in pediatric patients with asthma 6 months to 14 years of age. Safety and efficacy profiles in this age group are similar to those seen in adults.
Hepatic Insufficiency
: No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency.
Renal Insufficiency
: No dosage adjustment is recommended in patients with renal insufficiency.
Elderly use
: The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of montelukast are similar in elderly and younger adults. The plasma half-life of montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.
Montelukast is contraindicated in patients who are hypersensitive to any component of this product.
Common
: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.
Uncommon
: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.
Rare
: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.
Aeron is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with Aeron can be continued during acute exacerbations of asthma. While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, Aeron should not be abruptly substituted for inhaled or oral corticosteroids. Aeron should not be used as monotherapy for the treatment and management of exercise induced bronchospasm. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Aeron. Although Aeron is effective in improving airway function in asthmatics with documented aspirin sensitivity, it has not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic patients.
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor (CysLT
1
). The cysteinyl leukotrienes (LTC
4
, LTD
4
, LTE
4
) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma & allergic rhinitis, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.